China Market Access After NRDL Maturity: What Comes After the Price Reset?

Gaining inclusion in China’s National Reimbursement Drug List (NRDL) is no longer the final victory for Western pharmaceutical companies; it is just the beginning.

Securing a spot on the list does not guarantee immediate hospital uptake, nor does it automatically eliminate patient affordability barriers.

This whitepaper explores the critical post-NRDL landscape and outlines actionable strategies for pharmaceutical leaders, including:

Navigating Operational Delays: Overcoming provincial platform updates, hospital committee evaluations, and dual-channel pharmacy hurdles.
Bridging Affordability Gaps: Addressing residual out-of-pocket costs using alternative access models, such as city supplementary insurance (Huiminbao).
Unlocking Real-World Evidence (RWE): Utilizing RWE to defend price value at renewal cycles, prevent severe price cuts, and accelerate clinician adoption.

Download the full whitepaper to learn how to transform NRDL access gains into sustained, long-term commercial success.

FILL THE FORM BELOW

First Name *

Last Name *

Company Street Address *

Company Suite/Office *

Company Postal/Zip Code *

Company City *

Company State *

Company Country *

By submitting this content request, I have legitimate interest in the content and agree that Precision AQ, their partners, and the creators of any other content I have selected may contact me regarding news, products, and services that may be of interest to me.

YesNo